Mortality in relation to hepatitis B virus (HBV) infection status among HIV-HBV co-infected patients in sub-Saharan Africa after immediate initiation of antiretroviral therapy
| dc.rights.license | open | en_US |
| dc.contributor.author | MOHAREB, A. M. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | KOUAME, Menan Gerard | |
| dc.contributor.author | GABASSI, A. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | GABILLARD, Delphine | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MOH, Desmorys Raoul | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BADJE, Anani Dodzi | |
| dc.contributor.author | EMIEME, A. | |
| dc.contributor.author | MAYLIN, S. | |
| dc.contributor.author | MENAN, H. | |
| dc.contributor.author | HYLE, E. P. | |
| dc.contributor.author | DELAUGERRE, C. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | DANEL, Christine | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | ANGLARET, Xavier | |
| dc.contributor.author | LACOMBE, K. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | EHOLIE, Serge Paul | |
| dc.contributor.author | BOYD, A. | |
| dc.date.accessioned | 2021-03-08T11:15:39Z | |
| dc.date.available | 2021-03-08T11:15:39Z | |
| dc.date.issued | 2020-12-31 | |
| dc.identifier.issn | 1365-2893 (Electronic) 1352-0504 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/26454 | |
| dc.description.abstractEn | BACKGROUND: It is unknown how past and active hepatitis B virus (HBV) infection affect immunorecovery and mortality in people with HIV who initiate tenofovir-based anti-retroviral therapy (ART). METHODS: Using data collected between 2008- 2015, we studied people with HIV in sub-Saharan Africa initiating immediate ART in the Temprano randomized control trial. We classified participants into HBV groups at ART-initiation: hepatitis B surface antigen (HBsAg)-positive with HBV DNA ≥2000 IU/mL; HBsAg-positive with HBV DNA <2000 IU/ml; isolated HBcAb-positive; resolved infection (HBsAb-positive/HBcAb-positive); and HBV non-immune/vaccinated (HBcAb-). We compared square-root CD4-cell count increases using a mixed-effect, non-linear regression adjusted for age, sex, baseline CD4 cell count, and HIV RNA. We compared all-cause mortality using Bayesian parametric survival regression. RESULTS: Among 879 participants, 24 (2.7%) had HBsAg with high HBV DNA, 76 (8.6%) HBsAg with low HBV DNA, 325 (37.0%) isolated anti-HBcAb, 226 (25.7%) resolved HBV infection, and 228 (25.9%) HBV non-immune/vaccinated. We found no significant difference in CD4 cell increases between the four HBV-infection groups after adjustment (p=0.16). Participants with HBsAg and high HBV DNA had the highest incidence of all-cause mortality [1.9/100 person-years, 95%Credibile Interval (CrI)=1.0-3.4]. By comparison, incidence rates of mortality were reduced by 57% (95%CrI=-79%,-13%), 60% (95%CrI=-82%,-12%), and 66% (95%CrI=-84%,-23%) in those who had isolated anti-HBcAb-positive, resolved HBV infection, and HBV non-immune/vaccinated, respectively. CONCLUSION: Individuals with HIV and past HBV infection or isolated anti-HBcAb-positive serology, much like HBV non-immune/vaccinated, experience lower mortality than those with HBsAg and high HBV DNA. Additional HBV-related management would not be necessary for these individuals. | |
| dc.language.iso | EN | en_US |
| dc.title.en | Mortality in relation to hepatitis B virus (HBV) infection status among HIV-HBV co-infected patients in sub-Saharan Africa after immediate initiation of antiretroviral therapy | |
| dc.title.alternative | J Viral Hepat | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1111/jvh.13461 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 33382189 | en_US |
| bordeaux.journal | Journal of Viral Hepatitis | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | IDLIC | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.export | false | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Viral%20Hepatitis&rft.date=2020-12-31&rft.eissn=1365-2893%20(Electronic)%201352-0504%20(Linking)&rft.issn=1365-2893%20(Electronic)%201352-0504%20(Linking)&rft.au=MOHAREB,%20A.%20M.&KOUAME,%20Menan%20Gerard&GABASSI,%20A.&GABILLARD,%20Delphine&MOH,%20Desmorys%20Raoul&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||